Cargando…
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648492/ https://www.ncbi.nlm.nih.gov/pubmed/37958772 http://dx.doi.org/10.3390/ijms242115789 |
_version_ | 1785135353603031040 |
---|---|
author | Okon, Estera Gaweł-Bęben, Katarzyna Jarzab, Agata Koch, Wojciech Kukula-Koch, Wirginia Wawruszak, Anna |
author_facet | Okon, Estera Gaweł-Bęben, Katarzyna Jarzab, Agata Koch, Wojciech Kukula-Koch, Wirginia Wawruszak, Anna |
author_sort | Okon, Estera |
collection | PubMed |
description | Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anticancer properties have been successfully utilized in treating various medical conditions. Anthraquinone derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubiaceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of 1,8-dihydroanthraquinone derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents, in in vitro and in vivo BC models. The application of nanoparticles for in vitro and in vivo evidence in the context of 1,8-dihydroanthraquinone derivatives was also described. |
format | Online Article Text |
id | pubmed-10648492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106484922023-10-31 Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer Okon, Estera Gaweł-Bęben, Katarzyna Jarzab, Agata Koch, Wojciech Kukula-Koch, Wirginia Wawruszak, Anna Int J Mol Sci Review Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anticancer properties have been successfully utilized in treating various medical conditions. Anthraquinone derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubiaceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of 1,8-dihydroanthraquinone derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents, in in vitro and in vivo BC models. The application of nanoparticles for in vitro and in vivo evidence in the context of 1,8-dihydroanthraquinone derivatives was also described. MDPI 2023-10-31 /pmc/articles/PMC10648492/ /pubmed/37958772 http://dx.doi.org/10.3390/ijms242115789 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Okon, Estera Gaweł-Bęben, Katarzyna Jarzab, Agata Koch, Wojciech Kukula-Koch, Wirginia Wawruszak, Anna Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title | Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title_full | Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title_fullStr | Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title_full_unstemmed | Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title_short | Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer |
title_sort | therapeutic potential of 1,8-dihydroanthraquinone derivatives for breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648492/ https://www.ncbi.nlm.nih.gov/pubmed/37958772 http://dx.doi.org/10.3390/ijms242115789 |
work_keys_str_mv | AT okonestera therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer AT gawełbebenkatarzyna therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer AT jarzabagata therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer AT kochwojciech therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer AT kukulakochwirginia therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer AT wawruszakanna therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer |